Literature DB >> 3500130

Synergistic induction of interleukin-1 by endotoxin and toxic shock syndrome toxin-1 using rat macrophages.

D H Beezhold1, G K Best, P F Bonventre, M Thompson.   

Abstract

We studied interleukin-1 (IL-1) secretion by rat peritoneal exudate macrophages stimulated with purified toxic shock syndrome toxin-1 (TSST-1). TSST-1 was observed to be a more potent inducer of IL-1 than was endotoxin. The induction of IL-1 secretion by TSST-1 was not blocked by polymyxin B but could be blocked by monoclonal antibodies directed against TSST-1. Synergistic induction of IL-1 was observed when the cells were stimulated with TSST-1 and endotoxin. The sequence of addition was found to be important for the synergistic response. Enhanced IL-1 production was observed only when macrophages were exposed to endotoxin before or simultaneously with TSST-1. Prior exposure of macrophages to TSST-1 had no enhancing effect on endotoxin-induced IL-1 secretion. We conclude that stimulation of the macrophage by endotoxin enhances the responsiveness of the cells to TSST-1 and may thereby play a role in the pathogenesis of toxic shock syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500130      PMCID: PMC259999          DOI: 10.1128/iai.55.12.2865-2869.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Characterization of lymphocyte-activating factor (LAF) produced by the macrophage cell line, P388D1. I. Enhancement of LAF production by activated T lymphocytes.

Authors:  S B Mizel; J J Oppenheim; D L Rosenstreich
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

Review 2.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

3.  Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C.

Authors:  P M Schlievert
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

4.  Toxic-shock syndrome not associated with menstruation. A review of 54 cases.

Authors:  A L Reingold; B B Dan; K N Shands; C V Broome
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

5.  Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits.

Authors:  D F Scott; J M Kling; J J Kirkland; G K Best
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

6.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

Review 7.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

8.  Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases.

Authors:  K N Shands; G P Schmid; B B Dan; D Blum; R J Guidotti; N T Hargrett; R L Anderson; D L Hill; C V Broome; J D Band; D W Fraser
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

9.  Alteration of immune function by staphylococcal pyrogenic exotoxin type C: possible role in toxic-shock syndrome.

Authors:  P M Schlievert
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Effect of strain of Staphylococcus aureus on synergism with Candida albicans resulting in mouse mortality and morbidity.

Authors:  E Carlson
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

View more
  19 in total

Review 1.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

2.  Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody.

Authors:  G K Best; D F Scott; J M Kling; M R Thompson; L E Adinolfi; P F Bonventre
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

3.  Relative strength of the mitogenic and interleukin-2-production-inducing activities of staphylococcal exotoxins presumed to be causative exotoxins of toxic shock syndrome: toxic shock syndrome toxin-1 and enterotoxins A, B and C to murine and human T cells.

Authors:  T Uchiyama; Y Kamagata; X J Yan; A Kawachi; H Fujikawa; H Igarashi; M Okubo
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

4.  Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release.

Authors:  T Krakauer; B G Stiles
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 5.  Toxic shock syndrome.

Authors:  J K Todd
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

6.  A study on postoperative enteritis caused by methicillin-resistant Staphylococcus aureus.

Authors:  Y Takesue; T Yokoyama; T Kodama; T Santou; A Nakamitsu; Y Murakami; Y Imamura; K Miyamoto; M Okita; H Tsumura
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 7.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

8.  Murine macrophage activation by staphylococcal exotoxins.

Authors:  S D Fleming; J J Iandolo; S K Chapes
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Toxin involvement in methicillin-resistant Staphylococcus aureus enteritis in gastroenterological surgery.

Authors:  Y Takesue; T Yokoyama; T Kodama; T Santou; A Nakamitsu; Y Murakami; Y Imamura; K Miyamoto; M Okita; H Tsumura
Journal:  Gastroenterol Jpn       Date:  1991-12

10.  Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Authors:  B G Stiles; T Krakauer; P F Bonventre
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.